Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
Recruiting
N/A
Interventional Study
Chronic Leukemia
Acute Leukemia
Myeloproliferative Disorders
Lymphoproliferative Disorders
Myelodysplastic Disorders
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 1 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 250 (estimated)
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies co…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient aged \>1 year old, referred for evaluation to the University Hospital of Parma;
* Retrospective study: previously patients with hematological malignancies;
* Prospective study: 1) patients with clinical suspect of hematological malignancies which requires a diagnostic …
Contacts